Eva-Lotta Allan

Eva-Lotta Allan currently works at Maxion Therapeutics Ltd., as Non-Executive Chairman from 2023, Draupnir Bio ApS, as Non-Executive Chairman from 2021, Almirall SA, as Independent Non-Executive Director from 2020, Zelluna ASA, as Director from 2025, and Zelluna Immunotherapy AS, as Non-Executive Director.
Ms. Allan also formerly worked at C4X Discovery Holdings Ltd., as Non-Executive Chairman from 2018 to 2023, Novavax AB, as Non-Executive Director in 2010, Vertex Pharmaceuticals (Europe) Ltd., as Senior Director-Global Business Development from 2000 to 2006, The Bioindustry Association, as Director, Immunocore Holdings Plc, as Director & Chief Business Officer from 2013 to 2018, Aleta Biotherapeutics, Inc., as Non-Executive Director from 2019 to 2024, Circio Holding ASA, as Independent Director from 2015 to 2023, Crescendo Biologics Ltd., as Non-Executive Director, Karolinska Institutet, as Principal, Oxford Asymmetry International Plc, as Principal, Oxford GlycoSciences Plc, as Principal, GE Healthcare Ltd. (United Kingdom), as Principal, and Ablynx NV, as Chief Business Officer from 2010 to 2013.
Ms. Allan received her undergraduate degree from the University of Stockholm.